Sven F Garbade1, Nan Shen1,2, Nastassja Himmelreich1, Dorothea Haas1, Friedrich K Trefz1, Georg F Hoffmann1, Peter Burgard3, Nenad Blau4,5. 1. Dietmar-Hopp Metabolic Center and Centre for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany. 2. Department of Rehabilitation Medicine, Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Dietmar-Hopp Metabolic Center and Centre for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany. Peter.Burgard@med.uni-heidelberg.de. 4. Dietmar-Hopp Metabolic Center and Centre for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany. nenad.blau@med.uni-heidelberg.de. 5. University Children's Hospital Zürich, Zürich, Switzerland. nenad.blau@med.uni-heidelberg.de.
Abstract
PURPOSE: The nature of phenylalanine hydroxylase (PAH) variants determines residual enzyme activity, which modifies the clinical phenotype in phenylketonuria (PKU). We exploited the statistical power of a large genotype database to determine the relationship between genotype and phenotype in PKU. METHODS: A total of 9336 PKU patients with 2589 different genotypes, carrying 588 variants, were investigated using an allelic phenotype value (APV) algorithm. RESULTS: We identified 251 0-variants encoding inactive PAH, and assigned APVs (0 = classic PKU; 5 = mild PKU; 10 = mild hyperphenylalaninaemia) to 88 variants in PAH-functional hemizygous patients. The genotypic phenotype values (GPVs) were set equal to the higher-APV allele, which was assumed to be dominant over the lower-APV allele and to determine the metabolic phenotype. GPVs for 8872 patients resulted in cut-off ranges of 0.0-2.7 for classic PKU, 2.8-6.6 for mild PKU and 6.7-10.0 for mild hyperphenylalaninaemia. Genotype-based phenotype prediction was 99.2% for classic PKU, 46.2% for mild PKU and 89.5% for mild hyperphenylalaninaemia. The relationships between known pretreatment blood phenylalanine levels and GPVs (n = 4217), as well as tetrahydrobiopterin responsiveness and GPVs (n = 3488), were significant (both P < 0.001). CONCLUSIONS: APV and GPV are powerful tools to investigate genotype-phenotype associations, and can be used for genetic counselling of PKU families.
PURPOSE: The nature of phenylalanine hydroxylase (PAH) variants determines residual enzyme activity, which modifies the clinical phenotype in phenylketonuria (PKU). We exploited the statistical power of a large genotype database to determine the relationship between genotype and phenotype in PKU. METHODS: A total of 9336 PKU patients with 2589 different genotypes, carrying 588 variants, were investigated using an allelic phenotype value (APV) algorithm. RESULTS: We identified 251 0-variants encoding inactive PAH, and assigned APVs (0 = classic PKU; 5 = mild PKU; 10 = mild hyperphenylalaninaemia) to 88 variants in PAH-functional hemizygous patients. The genotypic phenotype values (GPVs) were set equal to the higher-APV allele, which was assumed to be dominant over the lower-APV allele and to determine the metabolic phenotype. GPVs for 8872 patients resulted in cut-off ranges of 0.0-2.7 for classic PKU, 2.8-6.6 for mild PKU and 6.7-10.0 for mild hyperphenylalaninaemia. Genotype-based phenotype prediction was 99.2% for classic PKU, 46.2% for mild PKU and 89.5% for mild hyperphenylalaninaemia. The relationships between known pretreatment blood phenylalanine levels and GPVs (n = 4217), as well as tetrahydrobiopterin responsiveness and GPVs (n = 3488), were significant (both P < 0.001). CONCLUSIONS: APV and GPV are powerful tools to investigate genotype-phenotype associations, and can be used for genetic counselling of PKU families.
Authors: L R Desviat; B Pérez; M J García; M Martínez-Pardo; A Baldellou; J Arena; P Sanjurjo; J Campistol; M L Couce; A Fernández; J Cardesa; M Ugarte Journal: Eur J Hum Genet Date: 1997 Jul-Aug Impact factor: 4.246
Authors: P Hardelid; M Cortina-Borja; A Munro; H Jones; M Cleary; M P Champion; Y Foo; C R Scriver; C Dezateux Journal: Ann Hum Genet Date: 2008-01 Impact factor: 1.670
Authors: Alicia Hillert; Yair Anikster; Amaya Belanger-Quintana; Alberto Burlina; Barbara K Burton; Carla Carducci; Ana E Chiesa; John Christodoulou; Maja Đorđević; Lourdes R Desviat; Aviva Eliyahu; Roeland A F Evers; Lena Fajkusova; François Feillet; Pedro E Bonfim-Freitas; Maria Giżewska; Polina Gundorova; Daniela Karall; Katya Kneller; Sergey I Kutsev; Vincenzo Leuzzi; Harvey L Levy; Uta Lichter-Konecki; Ania C Muntau; Fares Namour; Mariusz Oltarzewski; Andrea Paras; Belen Perez; Emil Polak; Alexander V Polyakov; Francesco Porta; Marianne Rohrbach; Sabine Scholl-Bürgi; Norma Spécola; Maja Stojiljković; Nan Shen; Luiz C Santana-da Silva; Anastasia Skouma; Francjan van Spronsen; Vera Stoppioni; Beat Thöny; Friedrich K Trefz; Jerry Vockley; Youngguo Yu; Johannes Zschocke; Georg F Hoffmann; Sven F Garbade; Nenad Blau Journal: Am J Hum Genet Date: 2020-07-14 Impact factor: 11.025
Authors: Saskia B Wortmann; Brigitte Meunier; Lamia Mestek-Boukhibar; Florence van den Broek; Elaina M Maldonado; Emma Clement; Daniel Weghuber; Johannes Spenger; Zdenek Jaros; Fatma Taha; Wyatt W Yue; Simon J Heales; James E Davison; Johannes A Mayr; Shamima Rahman Journal: Am J Hum Genet Date: 2020-01-30 Impact factor: 11.025
Authors: Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara Journal: Hum Genomics Date: 2022-07-19 Impact factor: 6.481
Authors: Julia C van Campen; Elizabeth S A Sollars; Rebecca C Thomas; Clare M Bartlett; Antonio Milano; Matthew D Parker; Jennifer Dawe; Peter R Winship; Gerrard Peck; Darren Grafham; Richard J Kirk; James R Bonham; Anne C Goodeve; Ann Dalton Journal: Int J Neonatal Screen Date: 2019-11-05
Authors: Jerry Vockley; Steven F Dobrowolski; Georgianne L Arnold; Ruben Bonilla Guerrero; Terry G J Derks; David A Weinstein Journal: Mol Genet Metab Date: 2019-07-19 Impact factor: 4.797